sur MedMira, Inc. (CVE:MIR)
MedMira Reports First Quarter Results for FY2026
MedMira Inc., based in Halifax, Nova Scotia, has announced the financial results for its first quarter ending October 31, 2025. The company received Health Canada approval for its Reveal® TP syphilis rapid test during this period, enabling its distribution across Canada.
The first clinical trial phase of the Multiplo® Complete Syphilis Antibody Test was completed, with favorable evaluations published. MedMira has also initiated the second trial phase to support regulatory submissions. Additionally, the firm is advancing the commercialization of its MiROQ technology focused on enhancing diagnostic speed and reliability.
Financially, the company reported a revenue decrease, ending the quarter with $54,208, down from the previous year's $61,723. Operating expenses reduced to $635,122, and the net loss was $813,134, an improvement compared to last year’s $1.3 million loss. Overall, liabilities increased, further impacting the working capital deficit.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de MedMira, Inc.